Teva Pharmaceutical Industries Limited (NYSE:TEVA) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Teva Pharmaceutical Industries Limited to reach your target.
Based on historical returns, we believe that Teva Pharmaceutical Industries Limited can grow its free cash at a rate of about 1%. That's positive!
| Advantages | Disadvantages | Neutral |
|---|---|---|
|
|
|
| TEVA Price (Teva Pharmaceutical Industries Limited stock price per share) |
$38.54 | |
|
|
TEVA Fair Price (based on intrinsic value) |
$72.18 |
| TEVA Safety Price (based on a variable margin of safety) | $43.31 | |
|
Try your own return
The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value. Value per share: |
||
| PE Ratio versus Sector | 342% higher than other Healthcare stocks | |
| PE Ratio versus Industry | 1186% higher than other Drug Manufacturers - General stocks | |
| Cash Yield | 13.52% | |
| Free Cash Flow Jitter | 68% | |
In the six months to 2026-11-22, no insider bought shares, and 9 insiders sold in 11 trades, about $7.1 million.
The six months before that had 0 buys and 39 sales.
Open-market buys and sells reported by Teva Pharmaceutical Industries Limited's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-08-21 | Weiss Amir (Chief Accounting Officer) | Sell | 6,945 | $37.61 |
| 2026-08-21 | Weiss Amir (Chief Accounting Officer) | Sell | 2,500 | $37.63 |
| 2026-08-21 | Satchi-Fainaro Ronit | Sell | 415 | $37.25 |
| 2026-08-17 | Lippman Evan (EVP, Business Development) | Sell | 18,600 | $36.57 |
| 2026-08-05 | Zaks Tal Zvi | Sell | 17 | $34.87 |
| 2026-08-03 | Hughes Eric A (See "Remarks") | Sell | 25,578 | $34.88 |
| 2026-08-03 | Jover Placid (See "Remarks") | Sell | 12,827 | $34.88 |
| 2026-06-18 | Shields Matthew (EVP, Global Operations) | Sell | 9,989 | $32.19 |
| 2026-06-11 | Kalif Eliyahu Sharon (EVP, Chief Financial Officer) | Sell | 106,563 | $34.10 |
| 2026-06-05 | Francis Richard D (President and CEO) | Sell | 6,153 | $34.35 |
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 27,739,194 shares shorted. With 1,090,551,317 shares available for purchase and an average trading volume over the past 10 trading days of 8,043,120, it would take at least 3.4 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
Each year names the SEC filer that reported it, so a change of filer shows up here.
| Fiscal year | SEC filer (CIK) | Free cash flow (USD millions) |
|---|---|---|
| 2016 | 818686 | 2,989 |
| 2017 | 818686 | 1,338 |
| 2018 | 818686 | 1,637 |
| 2019 | 818686 | 10.2 |
| 2020 | 818686 | 510 |
| 2021 | 818686 | 160 |
| 2022 | 818686 | 1,017 |
| 2023 | 818686 | 820 |
| 2024 | 818686 | 705 |
| 2025 | 818686 | 1,122 |
Download the yearly data as CSV.
How to read this: what free cash flow is, why earnings matter.
Over the 3 fiscal years from 2016 to 2025 with positive net income, operating cash flow totaled $6,337 million against net income of $2,156 million, or 2.94 times. Net income was negative in 7 of the 10 years, and those years are left out of the ratio.
In 2025, capital expenditures were $501 million, 30.4% of operating cash flow of $1,649 million, which leaves an estimated $1,148 million after capex. Across the 10 years with reported capex, it averaged 35.9% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2016 | 329 | 3,890 | 901 | 11.82 |
| 2017 | -16,265 | 2,225 | 874 | n/a |
| 2018 | -2,150 | 2,446 | 651 | n/a |
| 2019 | -999 | 748 | 525 | n/a |
| 2020 | -3,990 | 1,216 | 578 | n/a |
| 2021 | 417 | 798 | 562 | 1.91 |
| 2022 | -2,446 | 1,590 | 548 | n/a |
| 2023 | -559 | 1,368 | 526 | n/a |
| 2024 | -1,639 | 1,247 | 498 | n/a |
| 2025 | 1,410 | 1,649 | 501 | 1.17 |
How to read this: why companies buy back shares, dividend yield explained.
Over the 3 fiscal years from 2016 to 2018 with dividend or share repurchase facts, estimated free cash flow totaled $5,964 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.
In the 3 of those years with dividend payment facts, dividends paid totaled $2,216 million, 37.2% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 3 of those 3 years.
In 2018, dividends paid were $12 million, 0.7% of estimated free cash flow of $1,637 million.
| Fiscal year | Estimated free cash flow (USD millions) | Dividends paid (USD millions) | Cash spent repurchasing shares (USD millions) | Total returned (USD millions) | Total as a percent of estimated free cash flow |
|---|---|---|---|---|---|
| 2016 | 2,989 | 1,303 | n/a | 1,303 | 43.6% |
| 2017 | 1,338 | 901 | n/a | 901 | 67.4% |
| 2018 | 1,637 | 12 | n/a | 12 | 0.7% |
Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.
How to read this: earnings and margins.
Revenue was $21,903 million in 2016 and $17,258 million in 2025, a compound annual growth rate of -2.6% over 9 years.
Revenue rose 4.3% from 2024 to 2025.
Our estimated free cash flow was $1,122 million in 2025, 6.5% of revenue. In 2016 the estimated margin was 13.6%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2016 | 21,903 | 2,989 | 13.6% |
| 2017 | 21,853 | 1,338 | 6.1% |
| 2018 | 18,271 | 1,637 | 9.0% |
| 2019 | 16,887 | 10.2 | 0.1% |
| 2020 | 16,659 | 510 | 3.1% |
| 2021 | 15,878 | 160 | 1.0% |
| 2022 | 14,925 | 1,017 | 6.8% |
| 2023 | 15,846 | 820 | 5.2% |
| 2024 | 16,544 | 705 | 4.3% |
| 2025 | 17,258 | 1,122 | 6.5% |
How to read this: how debt and assets are compared, the current ratio.
In 2025, cash and equivalents were $3,556 million against total liabilities of $32,834 million, or 10.8% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 80.6% of total assets in 2025, compared with 73.5% in 2017, an increase of 7.1 percentage points.
Stockholders equity was $7,914 million in 2025, compared with $18,745 million in 2017, a fall of 57.8%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 4.7% in 2025. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2017 | 70,615 | 963 | 51,870 | 18,745 |
| 2018 | 60,683 | 1,782 | 44,889 | 15,794 |
| 2019 | 57,470 | 1,975 | 42,407 | 15,063 |
| 2020 | 50,640 | 2,177 | 39,579 | 11,061 |
| 2021 | 47,666 | 2,165 | 36,422 | 11,244 |
| 2022 | 45,932 | 2,801 | 37,334 | 8,598 |
| 2023 | 43,479 | 3,226 | 35,353 | 8,126 |
| 2024 | 39,326 | 3,300 | 33,606 | 5,380 |
| 2025 | 40,748 | 3,556 | 32,834 | 7,914 |
How to read this: discounted cash flow, intrinsic value.
At today's price of $38.54, our model's value equals that price if free cash flow grows an average of -8.7 percent a year over the 10 projection years. Our model assumes 1.5 percent a year for this stock, so the price implies growth of -8.7 percent, which is below the 1.5 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.
A negative rate means the price matches our model's value only if free cash flow shrinks by that average each year over the 10 years.
The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.
The model starts from the company's average free cash flow of $6,078 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.
The baseline is the company's average free cash flow, and cyclical companies can mislead it.
| Case | Price per share | Average annual free cash flow growth |
|---|---|---|
| 20 percent below the current price | $30.83 | -12.8% |
| Current price | $38.54 | -8.7% |
| 20 percent above the current price | $46.25 | -5.5% |
| Our model (stored fair price) | $72.18 | 1.5% |
Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.
At $38.54, Teva Pharmaceutical Industries Limited trades below our safe value estimate of $43.31 and our fair value estimate of $72.18.
Every one of the 10 fiscal years we have for Teva Pharmaceutical Industries Limited under its current filer shows positive free cash flow.
The latest three years average $882 million in free cash flow against $1,988 million for the earliest three, which is a sharp decline.
Year-to-year variability in free cash flow is volatile, measured at 68%.
Our value investing guide explains how to test these numbers against the filings themselves.
We do not have a dividend yield for Teva Pharmaceutical Industries Limited.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 342% above the average for stocks in the Healthcare sector.
Its trailing P/E ratio is 1186% above the average for stocks in the Drug Manufacturers - General industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Teva Pharmaceutical Industries Limited, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Limited (TEVA) | 44,970 | 89.6 | - | 13.5% | 47% below |
| Zoetis (ZTS) | 32,144 | 13.5 | 2.6% | - | 865% above |
| United Therapeutics Corporation (UTHR) | 23,625 | 20.9 | - | 1.5% | 30% above |
| Viatris (VTRS) | 22,505 | - | 2.4% | - | 2% below |
| Jazz Pharmaceuticals plc (JAZZ) | 14,780 | 68.1 | - | 3.4% | 53% below |
| Elanco Animal Health Incorporated (ELAN) | 12,866 | - | - | - | 96% above |
| Alkermes plc (ALKS) | 7,552 | - | - | 1.5% | 315% above |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 818686.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: TEVA annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Teva Pharmaceutical Industries Limited have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to TEVA: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is the Difference Between Trading Stocks and Investing?
Why Do Companies Perform Stock Buybacks?
How Does Portfolio Churning Affect Your Returns?
How Do Tariffs Affect the Stock Market?
DCA vs Lump Sum: 155 Years of S&P 500 Historical Data
How to Invest $1000 in the Stock Market